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LABORATORY INVESTIGATION
In vivo renal angiotensin converting enzyme activity decreases
in glycerol-induced acute renal failure
ROBERT L. BAINowsKI and CHRISTOF WESTENFELDER
Section of Nephrology, Veterans Administration and University of Utah Medical Centers, Salt Lake City, Utah, USA
In vivo renal angiotensin converting enzyme activity decreases in
glycerol-induced acute renal failure. We previously demonstrated that
intrarenal angiotensin II generation during glycerol-induced acute renal
failure was attenuated, which may have resulted from the inability of
intrarenal converting enzyme to convert renal angiotensin I to angio-
tensin II. In order to test this hypothesis in vivo, we determined the
ability of the kidney to convert angiotensin I to angiotensin II by
measuring the decrease in renal cortical blood flow (RCBF) in response
to exogenous angiotensin I administration. Changes in RCBF were
monitored by laser-Doppler velocimetry. Three groups of rats were
studied: Group I, controls (N = 7); 24 hours prior to study Group II
animals were injected with 50% glycerol, 8 mI/kg i.m. (N = 4); and
Group III rats were injected with mercuric chloride, 3 mg/kg s.c. (N =
5). All experimental animals had a three- to sixfold rise in serum
creatinine. Mean glomerular filtration rate (GFR) of the left and right
kidney in control rats was 0.7 and 0.7 mI/mm, respectively. Twenty-
four hours after glycerol, GFR was 0.2 mI/mm in the left kidney and 0.2
mI/mm in the right kidney. In HgCI2 treated rats GFR was 0.1 mI/mm in
the left kidney and 0.1 ml/min in the right kidney. Each of the following
maneuvers elicited a similar rise in blood pressure in Groups I through
III. Specifically, when first angiotensin 1(4 g/kg/min) was infused for
three minutes; second, when 10 minutes later angiotensin 1(5 g) was
directly applied on the left kidney; and third, when angiotensin 11(5 g)
was topically administered. The subsequent administration of enalap-
rilat (10 tg) onto the surface of the kidney attenuated the blood pressure
rise in response to angiotensin I but not to angiotensin II administration,
confirming that this method indeed assessed renal angiotensin convert-
ing enzyme activity. In rats with acute renal failure, the corresponding
angiotensin I, that is, angiotensin Il-induced fall in RCBF, as measured
by laser-Doppler velocimetry, was significantly diminished. On the
other hand, the RCBF response to angiotensin II (topical) was pre-
served in glycerol treated and decreased in HgCl2 treated animals.
These data demonstrate therefore that the topical administration of Al
in both models of ARF elicited a similar but decreased (when compared
to controls) RCBF response. The responsible mechanism for these
observations was a fall in renal converting enzyme activity in glycerol
treated rats and a reduced sensitivity to angiotensin II in HgC12 treated
rats. Whether these newly described mechanisms contribute to the fall
in GFR in these models of ARF is unknown.
Clinical acute renal failure (ARF) has remained a common
and serious syndrome associated with high morbidity and
mortality [1]. The principle feature of ARF is the marked
reduction of glomerular filtration rate (GFR) [21. Although
many theories have been advanced to explain the reduced GFR
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in ARF, the pathogenesis of this syndrome remains incom-
pletely understood. The suggestion that abnormalities of the
renal circulation contribute substantially to the impairment of
GFR in ARF has recently been reemphasized [3—6].Alterations
in the determinants of GFR in ARF (that is, a decrease in
hydrostatic pressure and glomerular ultrafiltration coefficient,
Kf) by activation of the renin-angiotensin system have been
demonstrated. These changes in glomerular hemodynamics
have in part been attributed to the local, intrarenal generation of
angiotensin II. Other recognized mechanisms that contribute to
the reduction of GFR are tubular obstruction and backleak of
ultrafiltrate.
Nevertheless it is becoming increasingly clear that there
exists an intrarenal paracrine system which can generate angio-
tensin II independently of the classical extrarenal pathway [7,
8]. All the components necessary for the intrarenal generation
of angiotensin II reside in the kidney [9—151. As the renin-
angiotensin system represents an enzyme cascade, the genera-
tion of intrarenal angiotensin II depends on renin and angio-
tensin converting enzyme activity. It is probable, therefore,
that changes in angiotensin converting enzyme activity could
regulate the generation of intrarenal angiotensin II.
The primary support for the hypothesis that the intrarenal
renin-angiotensin system is involved in the pathogenesis of
ARF is derived from experiments in which dietary manipulation
of the renin angiotensin system altered the course of experi-
mental ARF [2, 16]. Chronic salt loading, which depressed renal
renin content, afforded protection while volume depletion,
which increased renin activity, increased the severity of ARF.
Recent studies, however, have indicated that renal renin deple-
tion with salt loading is not essential for protection from ARF
[17, 18]. Furthermore, the administration of angiotensin II
antagonists or angiotensin converting enzyme inhibitors has
failed to alter the course of glycerol-induced ARF [19—21].
Data from our laboratory in a model of non-oliguric glycerol-
induced ARF in rats showed that intrarenal renin activity and
angiotensin I levels were elevated during the course of ARF,
while the concentration of intrarenal angiotensin II remained
unaltered [22]. The apparent inability of the kidney to generate
angiotensin II, while "adequate" levels of angiotensin I are
observed, may have at least two possible explanations: 1) the
kinetic properties of intrarenal angiotensin converting enzyme
may be altered in ARF, thereby limiting synthesis of angio-
tensin II; or 2) there may be accelerated breakdown of angio-
tensin II by angiotensinases. In order to distinguish between
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these possibilities, we determined in the present study whether
the ability of the kidney to convert angiotensin I to II in rats
with non-oliguric glycerol- or HgC12-induced ARF is altered.
The decrease in renal cortical blood flow (RCBF) that occurs
when exogenous angiotensin I is administered, was used as a
marker of intrarenal angiotensin II generation, which in turn is
a function of converting enzyme activity. Changes in RCBF
were measured by laser-Doppler velocimetry. We also deter-
mined whether the response of RCBF to angiotensin II is
altered in ARF.
Methods
Adult male Sprague-Dawley rats weighing between 250 and
300 g were maintained on a diet of regular rat chow with free
access to water. They were divided into three groups. Group I
(N = 7) were controls that received an injection of normal saline
(8 mllkg body wt, i.m.). Non-oliguric ARF was produced in rats
of Group II (N = 4) by an injection of 50% glycerol in tap water
(8 mI/kg body wt, i.m.). Renal failure was produced in rats of
Group III (N = 5) by an injection of HgCl2 (3 mg/kg body wt,
s.c.).
Twenty-four hours after injection animals were anesthetized
with mactin (100 mg/kg i.p.), a tracheostomy was performed
and catheters (PE 50) were positioned in the carotid artery for
blood pressure measurement and in both jugular veins for
infusion of test substances and fluid replacement. A laparotomy
was performed and both ureters were cannulated with PE 10
tubing. The left kidney was exposed for placement of the laser
microprobe.
Measurement of GFR with [125J] iothalamate has been previ-
ously described [23]. Blood pressure was monitored via a
Statham pressure transducer (P23 Db, Statham Instruments,
Oxnard, California, USA) interfaced with a Beckman Model
R51 1A polygraph (Beckman Instruments, Fullerton, California,
USA). The rats were placed on a heated table to maintain body
temperature at 37°C.
RCBF was measured with a MedPacific LDS000 laser-Dopp-
ler blood perfusion monitor (MedPacific Corp., Seattle, Wash-
ington, USA). The laser-Doppler microprobe was held in a
micromanipulator to facilitate placement of the probe on the
surface of the kidney.
The principles of the laser-Doppler method for measurement
of tissue blood flow have been described before [24]. In short,
a small area of tissue, approximately 1 mm in diameter is
illuminated by the beam of a helium-neon laser via an optical
fiber. As light enters the tissue, photons are scattered in a
random fashion by moving red blood cells and fixed tissue cells.
A portion of the scattered light is picked up by multiple fibers
..
Fig. 1. Experimental protocol showing the
sequence of angiotensin administration. MK
422 = Enalaprilat.
which return this light to a photodetector. The backscattered
light consists of Doppler-shifted light, which has interacted with
moving red cells, and unshifted light, which has been scattered
by fixed cells. The photons mix on the surface of the photo-
detector and generate a signal. The laser-Doppler instrument
processes the audio frequency spectrum of the signal and
outputs the processed signal to a digital readout and strip chart
recorder. The processed signal in millivolts, which is propor-
tional to red blood cell velocity, was expressed as the percent
reduction of RCBF from normal to zero flow. Zero flow was
established by momentary occlusion of the renal artery. There
is no dependence of the output signal (flow parameter) on the
orientation of the renal cortex in relation to the probe because
random scattering and multidirectional flow of blood is not a
measurement parameter. The penetration depth of laser light
for the renal cortex has been previously estimated at 1 mm [24].
Experimental protocol
Baseline blood pressure and superficial RCBF were moni-
tored followed by a three minute systemic infusion (4 z.g/kg/
mm) of angiotensin I (Fig. 1-I). Recovery of blood pressure and
RCBF was complete within 10 minutes after the infusion. Next
angiotensin I (5 g in 5 p.1) was applied on the surface of the
kidney (Fig. 1-Il). Blood pressure and RCBF were monitored
for 10 minutes. When all variables returned to baseline, enal-
aprilat (10 p.g in 10 p.l) was applied on the surface of the kidney.
The three-minute systemic infusion of angiotensin I was re-
peated 10 minutes after enalaprilat (Fig. 1-Ill), followed by a 10
minute recovery period. Angiotensin I (5 p.g in 5 p.l) was then
applied to the surface of the kidney and the response monitored
for 10 minutes (Fig. 1-IY). Finally, angiotensin 11(5 p.g in 5 p.1)
was applied to the surface of the kidney (Fig. 1-V).
Plasma creatinine was determined by a high performance
liquid chromatographic method [251. All data are expressed as
means SEM. Statistical analysis was performed by analysis of
variance and Student's t-test for independent and dependent
variables. A probability of < 0.05 between analyzed data means
was considered significant.
Results
Group I
Sham-injected control animals had a serum creatinine of 0.4
0.1 mg/dl and a GFR of 0.7 0.1 and 0.7 0.1 ml/min in the
left and right kidney, respectively. Baseline mean arterial blood
pressure was 122.4 4.3 mm Hg.
Systemic infusion of angiotensin I caused a prompt increase
in blood pressure by 49.9 3.3 mm Hg and a decrease in RCBF
Total time
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Fig. 2. Blood pressure response to angioensin and enalaprilat admin-
istration in control (Group I), glycerol (Group II), and mercuric
chloride (Group III) treated animals. See Figure 1 for explanation of
Roman numerals. *P < 0.05 versus the control group (Group I).
by 58.5 4.8% in control animals (Figs. 2-I and 3-I). This rise
in blood pressure always preceded the change in RCBF by
approximately five seconds when angiotensin I was intrave-
nously administered, which in turn reflected systemic conver-
sion of angiotensin I to angiotensin II. Angiotensin I placed on
the surface of the kidney (Figs. 2-I! and 3-Il) caused a signifi-
cant increase (P < 0.05) in blood pressure by 24.6 3.6 mm Hg
and decreased RCBF by 44.1 4.0%. The decrease in RCBF
with application of angiotensin I on the surface of the kidney
always preceded any blood pressure change by approximately
20 seconds, indicating intrarenal conversion of angiotensin Ito
angiotensin II. Therefore, the reported RCBF responses to
topical angiotensin I or II are only based on a 20 second interval
prior to the increase in systemic pressure to temporally separate
local from systemic angiotensin II generation. Application of
enalaprilat on the surface of the kidney significantly reduced (P
<0.05) the blood pressure rise (Figs. 2-Ill and 3-Ill) in response
to systemically-infused angiotensin I (blood pressure rose only
by 9.2 3.1 mm Hg), and the associated decrease of RCBF was
significantly reduced (renal blood flow fell only by 11.7 4.7%,
P < 0.05). The blood pressure increase (Fig. 2-IV) in response
to renal topical application of angiotensin I after enalaprilat
administration was reduced (blood pressure rose only by 9.6
3.7 mm Hg). The associated decrease in RCBF (Fig. 3-IV) was
15.9 3.4% of control, which demonstrated that intrarenal
converting enzyme activity was partially blocked by enalapri-
lat. Application of angiotensin II to the surface of the kidney
(Figs. 2-V and 3-V) caused a 22.9 4.7 mm Hg increase in
blood pressure and a decrease in RCBF by 38.8 5.9%, a
response not significantly different from that produced by
equimolar topical angiotensin I. These data demonstrated that
blood pressure and RCBF responses were attributable to the
conversion of angiotensin I to angiotensin II.
In four additional animals angiotensin II was topically admin-
istered both before and 25 minutes after enalaprilat to determine
Fig. 3. Renal cortical blood flow, determined by laser-Doppler veloci-
metry, in response to angiotensin and enalaprilat administration in
control (Group I), glycerol (Group II), and mercuric chloride (Group
III) treated animals. See Figure 1 for explanation of Roman numerals.
*D < 0.05 versus the control group (Group I).
the effects of the inhibitor on vascular reactivity to angiotensin
II. The decrease in RCBF in response to angiotensin II admin-
istration either before or after enalaprilat was not significantly
different (39.0 4.8% before and 41.2 5.1% after).
Group II
Animals treated with glycerol 24 hours prior to study had a
serum creatinine of 1.4 0.2 mg/dl (P < 0.05 vs. control rats)
and aGFR of 0.2 0.1 and 0.2 0.1 mI/mm of the left and right
kidney, respectively. All values differed significantly from those
in control rats (Group I). The baseline mean arterial blood
pressure of 91.7 10.5 mm Hg was significantly lower than the
mean blood pressure in control rats (P <0.05).
Systemic infusion of angiotensin I caused an increase in
blood pressure by 50.0 15.3 mm Hg (Fig. 2-I). RCBF
decreased by 29.1 10.4% in response to the infusion (Fig. 3-I).
Angiotensin I placed on the surface of the kidney increased
mean blood pressure by 23.1 5.4 mm Hg (Fig. 2-Il) and
decreased RCBF (Fig. 3-Il) by 23.7 9.0%, a value signifi-
cantly different from that obtained in control rats (P < 0.05).
Application of enalaprilat on the surface of the kidney signifi-
cantly reduced the blood pressure rise (Fig. 2-Ill) in response to
systemically infused angiotensin I (blood pressure increased
only by 8.8 3.7 mm Hg) and the decrease of RCBF (Fig. 3-Ill)
was attenuated significantly (RCBF decreased only by 11.5
1.6%, P < 0.05). The increase in blood pressure (Fig. 2-IV) in
response to the renal topical application of angiotensin I follow-
ing enalaprilat administration was reduced (blood pressure
increased only by 7.8 1.1 mm Hg) and RCBF (Fig. 3-IV) fell
only by 8.0 1.4%. Subsequent application of angiotensin II to
the surface of the kidney caused a 27.5 5.2 mm Hg increase
in blood pressure (Fig. 2-V) and a decrease in RCBF (Fig. 3-V)
of 40.2 8.1%, values which were not significantly different
from those produced by renal topical angiotensin I administra-
tion. Thus, when compared with controls (Figs. 3-V and 4-V),
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the sensitivity to angiotensin II was preserved at 24 hours after
glycerol.
Group III
Animals treated with HgC12 24 hours prior to study had a
serum creatinine of 2.5 0.4 mgldl and a GFR of 0.1 0.1 and
0.1 0.1 ml/min of the left and right kidney, respectively. All
values were significantly different (P < 0.05) from control
animals (Group I). Baseline mean arterial blood pressure was
111.0 5.9 mm Hg, a value not significantly different from the
mean blood pressure in control rats.
Systemic infusion of angiotensin I caused an increase in
blood pressure ofSl .0 5.4mmHg (Fig. 2-I). RCBF decreased
by 39.0 6.3% in response to the infusion (Fig. 3-I). Angioten-
sin I placed on the surface of the kidney increased blood
pressure by 17.0 3.0 mm Hg (Fig. 2-I!) and decreased RCBF
by 24.7 3.9% (Fig. 3-Il), values significantly different from
those obtained in control rats (P < 0.05). Application of
enalaprilat on the surface of the kidney significantly reduced the
blood pressure rise (Fig. 2-Ill) in response to systemically
infused angiotensin I (blood pressure rose only by 9.0 4.1 mm
Hg). There was a significant attenuation of the decrease in
associated RCBF (it decreased only by 6.3 2.7%, Fig. 3-Ill).
The increase in blood pressure (Fig. 2-IV) in response to renal
topical application of angiotensin I after enalaprilat administra-
tion was reduced (blood pressure increased only by 10.0 3.4
mm Hg). The simultaneous decrease in RCBF (Fig. 3-IV) was
reduced (it fell only by 5.2 1.6%). Subsequent application of
angiotensin II to the surface of the kidney caused a 30.0 4.7
mm Hg increase in blood pressure and a decrease in RCBF by
28.4 4.4%.
Both models of ARF (Groups II and III) exhibited decreased
RCBF changes in response to the topical administration of
angiotensin I (compared to controls, Group I, Fig. 3). This
observation could have resulted from either reduced intrarenal
angiotensin II generation, as a function of lowered converting
enzyme activity, or, alternatively, from decreased sensitivity to
angiotensin II. Because we administered identical quantities of
Al and All (5 g each), we were able to calculate the ratios
between angiotensin I- to angiotensin Il-induced decreases in
RCBF. This ratio distinguishes between these two possibilities,
that is, whether the obtained changes in RCBF are due to either
a decrease in renal converting enzyme activity or a fall in
angiotensin II sensitivity within each experimental group. Spe-
cifically, a ratio that is significantly less than that obtained in
controls suggests that conversion of angiotensin I to angiotensin
II is decreased. On the other hand, a ratio that is not different
from controls suggests that the observed changes in angiotensin
I-induced RCBF are due to decreased angiotensin II sensitivity
in ARF.
In controls (Group I) decreases in RCBF obtained with either
topical angiotensin I of angiotensin II were not significantly
different, thus rendering a RCBF angiotensin Ito angiotensin II
ratio of 1.28 0.2. In glycerol treated animals (group II),
decreases in RCBF obtained with topical angiotensin I were
significantly reduced both when compared to controls (Fig. 3)
and in comparison with the response obtained with topical
angiotensin II. From this a RCBF angiotensin Ito angiotensin II
ratio of 0.51 0.1 was obtained, which was significantly
different (P < 0.05) from the ratio in controls. In HgC12 treated
rats (group III) decreases in RCBF obtained with topical
angiotensin I were significantly reduced only when compared to
controls. Thus, a RCBF angiotensin Ito angiotensin II ratio of
1.04 0.3 was obtained, which was not different from that
calculated for controls.
Discussion
Continuous measurement of blood flow by laser-Doppler
velocimetry in the outer cortex of the rat kidney has been
previously carried out by other investigators [24, 26]. The
technique has also been used to monitor RCBF during the
administration of norepinephrine and angiotensin II (with and
without saralasin) [24, 26]. Resulting dynamic responses in
RCBF were consistent with the known pharmacologic actions
of these agents. The laser-Doppler method has been demon-
strated to be reliable for monitoring of relative tissue perfusion
in the rat kidney, even though a flow signal and not absolute
blood flow is measured.
The present study utilized the laser-Doppler velocimetry
technique in the evaluation of intrarenal angiotensin converting
enzyme activity during the maintenance phase of glycerol- and
HgCI2-induced ARF in the rat. We also tested the sensitivity of
the outer cortical circulation to angiotensin II under these
conditions. The conversion of angiotensin Ito angiotensin II (or
intrarenal angiotensin converting enzyme activity) was as-
sessed by observing the decrease in RCBF in response to
topical application of exogenous angiotensin I on the kidney
surface. The use of the laser-Doppler method to assess intrare-
nal converting enzyme activity is unique in that it can be used
to study the effects of local pharmacologic actions of angio-
tensins and converting enzyme inhibitors without interference
from systemic events. Successful converting enzyme inhibition
with enalapril confirmed that the observed responses were due
to the conversion of angiotensin I to angiotensin II and not due
to intrinsic angiotensin I activity. This is further corroborated
by the "normal" decrease in RCBF that was obtained when
angiotensin II was administered following enalaprilat applica-
tion. The administration of identical quantities of angiotensin I
and angiotensin II allowed calculation of the ratios between
angiotensin I- to angiotensin Il-induced decreases in RCBF.
This ratio distinguishes between a decrease in renal converting
enzyme activity or a fall in angiotensin II sensitivity within each
experimental group.
The current results confirm our earlier observations in the
glycerol model of ARF [221, in which we showed that intrarenal
angiotensin II was depressed in the maintenance phase of ARF.
Specifically, the generation of angiotensin II, a function of
intrarenal converting enzyme activity, was decreased, while the
sensitivity to angiotensin II was unaltered. In contrast, intrare-
nal converting enzyme activity was unchanged in HgCI2-in-
duced ARF, whereas the vascular angiotensin II sensitivity was
decreased. Whether in HgC12 treated animals there is in addi-
tion accelerated breakdown of angiotensins cannot be ruled out.
Our observations of decreased generation of or reduced respon-
siveness to angiotensin II in these two models of ARF may in
part explain why renal blood flow at 24 hours after both glycerol
or HgCI2 returns towards normal while GFR remains depressed
[27].
The pathogenesis of the defect in GFR in experimental ARF
is clearly multifactorial. There is considerable evidence to
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indicate that tubular obstruction in glycerol-induced ARF and
backleak of glomerular filtrate in HgC12-induced ARF contrib-
ute significantly to the decrease in GFR [271. The precise
mechanism by which reduced angiotensin converting enzyme
activity or the decrease in renal vascular sensitivity to angio-
tensin II may contribute to this decrease in GFR is less clear. It
is possible that in the maintenance phase of ARF, when the
kidney generates "insufficient" angiotensin II and/or "inade-
quately" degrades bradykinin, or is unable to respond normally
to angiotensin II, efferent arteriolar tone diminishes, which in
turn might contribute to the decrease in GFR in ARF.
Clinical studies have demonstrated that patients with severe
congestive heart failure and marked activation of the renin-
angiotensin system are at risk of developing ARF [28—30] when
converting enzyme inhibitors are administered. Under these
circumstances GFR is critically dependent on efferent arteriolar
constriction by angiotensin II. When angiotensin converting
enzyme was functionally suppressed by enalapril or captopril,
these patients developed renal insufficiency. The decline in
renal function was the result of reduced angiotensin Il-mediated
systemic and intrarenal vasoconstrictor effects, actions needed
to maintain renal perfusion pressure and GFR during low renal
perfusion.
The intrarenal biosynthesis of prostaglandins may also be
responsible for glomerular hemodynamic alterations that cause
a sustained decrease in GFR [31]. There were time dependent
increases in the biosynthesis of glomerular prostaglandin E2,
prostaglandin F2 and prostacyclin after uranyl nitrate admin-
istration. This rise in prostaglandins paralleled the fall in GFR.
A similar increase in glomerular eicosanoid biosynthesis was
observed in glycerol- and HgCl2-induced ARF [31, 32]. It was
suggested that the augmented biosynthesis of vasodilator eco-
sanoids (prostaglandin E2 and prostacyclin), that occurs in
response to a decrease in renal perfusion in ARF. led paradox-
ically to a further decrease in renal function via a prostaglandin-
dependent reduction in the glomerular ultrafiltration coefficient
[31].
Based on our data we suggest for the first time that intrarenal
angiotensin converting enzyme, at least in glycerol-induced
ARF, may be a key regulatory enzyme in the local production
of angiotensin II. This observation in turn emphasizes that the
tissue renin-angiotensin system [33] in experimental ARF may
be more important than previously thought. Establishment of
the exact pathogenic role of the tissue renin-angiotensin system
in ARF will require, however, further studies and development
of new experimental approaches.
It is also interesting to note that the magnitude of blood
pressure rise in response to systemic angiotensin I infusion was
of comparable magnitude in all three groups, while the associ-
ated decrease in RCBF was lessened in glycerol-induced ARF
(Group II). The latter probably reflects "normal" angiotensin II
generation by lung and circulating converting enzyme and a
simultaneous decrease in angiotensin II delivery to the kidney,
the likely result of lowered renal blood flow. Whether this
explanation pertains is unclear.
In summary, this study demonstrates for the first time that
the intrarenal conversion of angiotensin I to angiotensin II was
reduced in glycerol-induced ARF, while the RCBF response
(vascular sensitivity) to angiotensin II was preserved. It is
therefore suggested that alterations in intrarenal converting
enzyme activity are responsible for the reduction of intrarenal
angiotensin II in glycerol-induced ARF [22]. In contrast, the
mechanism responsible for the reduced RCBF response (angio-
tensin induced) in HgC12 ARF was a fall in sensitivity to
angiotensin II. Whether in HgC12 treated animals there is in
addition accelerated breakdown of angiotensins cannot be ruled
out. The extent to which these mechanisms contribute to the
observed fall in GFR in these experimental models of ARF is
unknown.
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